U.S. Markets open in 3 hrs 45 mins

Weekly Top Insider Buys Highlight for the Week of Feb. 8

- By Shuda Xia

The largest Insider Buys this week were for AT&T Inc. (NYSE:T), Biogen Inc. (BIIB), Abbott Laboratories (ABT) and Zimmer Biomet Holdings Inc. (ZBH).

AT&T Inc. (NYSE:T): Director Geoffrey Y. Yang bought 33,558 shares

Director Geoffrey Y. Yang bought 33,558 shares of AT&T stock on Feb. 4 at the average price of $29.79. The price of the stock has decreased by 1.14% since.


AT&T Inc. an American multinational telecommunications conglomerate that is the second largest provider of mobile telephone services and the largest provider of fixed telephone services in the U.S. It also provides broadband subscription television services through DirecTV. The company has a market capitalization of $214.45 billion, and as of Feb. 8 it traded at $29.45.

On Jan. 30 AT&T Inc. reported fourth quarter 2018 results. Diluted earnings per share for the quarter was $2.85 compared to diluted earnings per share of $4.76 during the same quarter the prior year. Cash from operations increased 15% from the same quarter the prior year to $43.6 billion. Capital expenditures for the quarter were $21.3 billion.

Biogen Inc. (BIIB): Director Alexander J. Denner bought 62,800 shares

Director Alexander J. Denner bought 62,800 shares of Biogen stock on Feb. 1 at the average price of $327.59. The price of the stock has decreased by 3.98% since.

Biogen Inc. is an American international biotechnology company specializing in the research, development and delivery of therapies for the treatment of neurodegenerative, hematologic and autoimmune diseases. Some of the products of the company include Alprolix, Avonex, Eloctate, Fampyra and Gazyva. The company has a market capitalization of $61.87 billion, and as of Feb. 8 it traded at $314.54.

On Jan. 29 Biogen Inc. reported full-year and fourth-quarter 2018 results. Total revenues for the year were $13.5 billion, a 10% increase from the previous year. Reported full year GAAP net income was $4.4 billion compared to $2.5 billion during the previous year. Diluted earnings per share for the year were $21.58 compared to $11.92 during the prior year.

Abbott Laboratories (ABT): Director John G. Stratton bought 3,455 shares

Director John G. Stratton bought 3,455 shares of Abbott Laboratories stock on Jan. 31 at the average price of $72.32. The price of the stock has increased by 1.22% since.

Abbott Laboratories is an American health care company that focuses on developing and marketing research-based drugs, medical devices and nutritional products. The company's in-vitro diagnostics business also performs immunoassays and blood screening. The company has a market capitalization of $128.56 billion, and as of Feb. 8 it traded at $73.20.

On Jan. 23 Abbott Laboratories reported financial results for the fourth quarter and full year ended Dec. 31, 2018. Full-year worldwide sales increased 11.6% from the prior year to $30.6 billion while fourth quarter worldwide sales increased 2.3% to $7.8 billion. GAAP diluted earnings per share for the full year 2018 was $1.31. During 2018, the company returned $2 billion to shareholders in the form of dividends and announced a 14.3% increase in its quarterly common dividend in December of 2018.

Zimmer Biomet Holdings Inc. (ZBH): Director Betsy J. Bernard bought 4,250 shares

Director Betsy J. Bernard bought 4,250 shares of Zimmer Biomet Holdings stock on Feb. 6 at the average price of $117.41. The price of the stock has increased by 1.92% since.

Zimmer Biomet Holdings Inc. is an American healthcare company that was spun off from Bristol-Myers Squibb in 2001. The company focuses on developing, manufacturing and marketing orthopedic reconstructive products and is a component of the S&P 500. The company has a market capitalization of $24.41 billion, and as of Feb. 8 it traded at $119.66.

On Feb. 1 Zimmer Biomet Holdings Inc. reported fourth-quarter and full-year 2018 results. Net sales were $2.071 billion for the fourth quarter, a 0.1% increase compared to net sales during the same quarter prior year. Diluted loss per share was $4.42 for the fourth quarter.

For the complete list of stocks that were bought by their company executives, go to: Insider Trades.

Disclosure: I do not own stock in any of the companies mentioned.

This article first appeared on GuruFocus.